UBS Group’s Prelude Therapeutics PRLD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $84.3K | Buy |
|
|||||
|
2025
Q1 | $73.8K | Buy |
|
|||||
|
2024
Q4 | $85.9K | Buy |
|
|||||
|
2024
Q3 | $14.5K | Sell |
|
|||||
|
2024
Q2 | $41.7K | Sell |
|
|||||
|
2024
Q1 | $74.2K | Sell |
|
|||||
|
2023
Q4 | $84.9K | Buy |
|
|||||
|
2023
Q3 | $22.9K | Buy |
|
|||||
|
2023
Q2 | $31K | Buy |
|
|||||
|
2023
Q1 | $5.59K | Sell |
|
|||||
|
2022
Q4 | $6.26K | Buy |
|
|||||
|
2022
Q3 | $0 | Sell |
|
|||||
|
2022
Q2 | $14K | Buy |
|
|||||
|
2022
Q1 | $1K | Sell |
|
|||||
|
2021
Q4 | $23K | Sell |
|
|||||
|
2021
Q3 | $1.16M | Buy |
|
|||||
|
2021
Q2 | $216K | Sell |
|
|||||
|
2021
Q1 | $968K | Buy |
|
|||||
|
2020
Q4 | $185K | Buy |
|
|||||
|
2020
Q3 | $43K | Buy |
|